Literature DB >> 21674006

Genome-wide association study of schizophrenia in Japanese population.

Kazuo Yamada1, Yoshimi Iwayama, Eiji Hattori, Kazuya Iwamoto, Tomoko Toyota, Tetsuo Ohnishi, Hisako Ohba, Motoko Maekawa, Tadafumi Kato, Takeo Yoshikawa.   

Abstract

Schizophrenia is a devastating neuropsychiatric disorder with genetically complex traits. Genetic variants should explain a considerable portion of the risk for schizophrenia, and genome-wide association study (GWAS) is a potentially powerful tool for identifying the risk variants that underlie the disease. Here, we report the results of a three-stage analysis of three independent cohorts consisting of a total of 2,535 samples from Japanese and Chinese populations for searching schizophrenia susceptibility genes using a GWAS approach. Firstly, we examined 115,770 single nucleotide polymorphisms (SNPs) in 120 patient-parents trio samples from Japanese schizophrenia pedigrees. In stage II, we evaluated 1,632 SNPs (1,159 SNPs of p<0.01 and 473 SNPs of p<0.05 that located in previously reported linkage regions). The second sample consisted of 1,012 case-control samples of Japanese origin. The most significant p value was obtained for the SNP in the ELAVL2 [(embryonic lethal, abnormal vision, Drosophila)-like 2] gene located on 9p21.3 (p = 0.00087). In stage III, we scrutinized the ELAVL2 gene by genotyping gene-centric tagSNPs in the third sample set of 293 family samples (1,163 individuals) of Chinese descent and the SNP in the gene showed a nominal association with schizophrenia in Chinese population (p = 0.026). The current data in Asian population would be helpful for deciphering ethnic diversity of schizophrenia etiology.

Entities:  

Mesh:

Year:  2011        PMID: 21674006      PMCID: PMC3108953          DOI: 10.1371/journal.pone.0020468

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Schizophrenia is a debilitating mental disorder characterized by psychotic manifestations including hallucinations, delusions, and cognitive deficits. Despite the high heritability of the disease estimated at up to 80%, key molecules and/or molecular pathways underlying the disease are still elusive. Candidate gene-based analyses have an inherent limitation, that is, we do not know the precise pathophysiological basis for the disease. However, through the rapid development of genotyping technology, it has become feasible to genotype hundreds of thousands of single nucleotide polymorphisms (SNPs) covering the whole human genome. A shift toward genome-wide association study (GWAS) from a gene-based approach is accelerated. To date, a number of GWASs of psychiatric disorders, including schizophrenia, have been reported [1], [2], [3], [4], [5], [6], [7]. These have produced substantial evidence for the association of the disease with specific risk loci. For instance, O'Donovan et al. reported the evidence for association around ZNF804A (p = 1.61×10−7) [2]. However, the protein encoded by ZNF804A is uncharacterized and its function is unknown. No functional candidate genes that stemmed from current understanding of schizophrenia pathophysiology surpassed the genome-wide significance level in that study. It is also noteworthy that many GWASs so far have potentially missed the true association of the genes with small effect, because of a stringent threshold. Conversely, a liberal threshold requires follow-up studies to eliminate false positives from genuine associations. Therefore, a simple procedure for overcoming this problem is the use of a multistage screening approach, using a modest threshold in each stage. In addition, case-control design is liable to population stratification, which can cause spurious associations. To eliminate false positives due to population stratification and other confounding factors, the transmission disequilibrium test (TDT) design that uses patients and their parents (trios) is preferable as an alternative approach. In this study, starting from a whole genome association survey of trio families, we carried out a staged association study for schizophrenia by analyzing three sets of samples, two from Japanese cohort and one from Chinese population, which is ethnically close to Japanese. All three sets of our samples showed a nominally significant association with a SNP on the ELAVL2 gene. This Asian GWAS of schizophrenia is hoped to provide a broader view of the genetic basis of schizophrenia, because schizophrenia GWASs to date are much accumulated in European descent.

Results

Stage I: GWAS of Japanese trio samples

Because of concerns regarding population stratification and other unknown confounding factors, we performed the first-stage screening restricted to pedigree trio samples comprising 120 families, each consisting of a patient with schizophrenia and their parents. All the subjects were Japanese and diagnosis of schizophrenia was carried out by at least two experienced psychiatrists according to DSM-IV criteria, on the basis of interview and medical records. The trios were initially genotyped using Affymetrix GeneChip Mapping 100 K Arrays. Out of a total of 115,770 SNPs, 97,963 SNPs were successfully genotyped. The rest, 17,807 SNPs, were nonpolymorphic in the Japanese population or failed at the genotyping stage. They were excluded from further analyses. We ranked genotyped SNPs on the basis of strength of association using the allelic association test. Nominally significant results were detected for 1,159 SNPs (p<0.01). Genotyping data yielded an average call rate of 96.6%, and apparent inheritance errors in trio samples were detected in <0.2% of all SNPs. A quantile-quantile (QQ) plot for association results is provided in Figure 1. The group of SNPs that slightly deviated from a diagonal straight line in the QQ plot are considered to reflect SNPs with weak genetic effects, and from the plot, it seems that there is not gross inflation of false-positive results derived from genotyping errors.
Figure 1

A quantile-quantile (QQ) plot for association results of the first-stage analysis.

The empirical and theoretical distributions are shown as dots and line, respectively.

A quantile-quantile (QQ) plot for association results of the first-stage analysis.

The empirical and theoretical distributions are shown as dots and line, respectively. The most significant p value was obtained for marker rs2174623 at 4q28.1 (p = 6.11×10−6), followed by markers rs883955 at Xq24 (p = 7.10×10−6) and rs10499585 at 7p15.1 (p = 3.14×10−5). However, no human reference gene was located at these regions. P values for the TDT analyses of schizophrenia trios for all 97,963 SNPs are shown in a Manhattan plot (Figure 2).
Figure 2

Results of whole genome association scan for Japanese trio samples.

A Manhattan plot is shown. SNPs from each chromosome are represented by different colors and ordered by physical positions.

Results of whole genome association scan for Japanese trio samples.

A Manhattan plot is shown. SNPs from each chromosome are represented by different colors and ordered by physical positions.

Stage II: Replication in Japanese case-control samples

We selected 1,632 SNPs from the first-stage screening [1,159 SNPs of p<0.01, and 473 SNPs of p<0.05 located in previously reported linkage regions [8], [9]]. In the second-stage analysis, we have taken advantage of an affordable multiplex genotyping platform (Illumina Bead Array). The second sample consisted of 506 patients with schizophrenia and 506 age- and sex-matched controls of Japanese origin. Control subjects were recruited from hospital staff and volunteers who had no family history of psychoses. They showed no current or past evidence of psychoses, during brief interviews by expert psychiatrists. In this experiment, 120 SNPs have dropped owing to the low designability of target SNPs and 40 SNPs could not be genotyped. Accordingly, 1,472 SNPs were successfully genotyped in an independent Japanese case-control sample. Sixty-nine SNPs located on autosomes and 17 SNPs located on chromosome X showed a nominal significance of p<0.05 (Tables S1, S2). It may be reasonable not to declare a compelling association regarding these SNPs because of multiple testing, therefore, the interpretation of data must be made with caution. The top 20 SNPs are listed in Table 1. The most significant p value in the second-stage analysis was obtained for the SNP in the ELAVL2 [(embryonic lethal, abnormal vision, Drosophila)-like 2] gene located on 9p21.3 (p = 0.00087).
Table 1

The top 20 signals in the two-stage association analyses.

RANKSNP IDPosition p valueGeneHWE p value
1st stage2nd stageControlCase
1rs104918179p21.30.006490.00087 ELAVL2 0.5760.879
2rs1050755913q14.20.009330.000940.4980.382
3rs92960216p21.320.010300.00158 C6orf10 0.2400.035
4rs104971062q23.30.000910.00181 FMNL2 0.1590.280
5rs18992642p120.020100.002400.6790.972
6rs9506515p15.320.000140.002990.7130.256
7rs14495313p24.30.000240.002990.4390.531
8rs797095412p12.10.005110.00329 IFLTD1 0.9000.021
9rs48821211q22.30.015900.003860.3100.658
10rs76958704q32.10.009530.00419 GRIA2 0.8430.975
11rs66064711q22.30.015100.005300.3450.801
12rs105176684q32.10.003760.005490.8750.682
13rs228996511p15.10.002860.00678 IGSF22 0.2730.711
14rs22921013p25.20.011400.00679 PPARG 0.8170.550
15rs22353946p24.10.011100.00697 C6orf105 0.3060.556
16rs104967612q22.10.032500.009120.0990.678
17rs10480766p21.10.002250.00945 ENPP4 0.9740.876
18rs3481165p15.20.002700.009520.2070.918
19rs1050584512p12.20.008380.010100.3920.868
20rs31066532q24.10.004650.01194 KCNJ3 0.7100.199

Rank is ordered according to the results of the second-stage analysis.

SNP information is listed based on UCSC Feb. 2009 (http://genome.ucsc.edu/).

P values of the 1st stage are calculated by Transmission Disequilibrium Test (TDT).

P values of the 2nd stage are calculated by Fisher's exact test.

HWE: Hardy Weinberg Equilibrium. Departures from the assumption of HWE are evaluated based on the data from the 2nd stage case-control samples.

Rank is ordered according to the results of the second-stage analysis. SNP information is listed based on UCSC Feb. 2009 (http://genome.ucsc.edu/). P values of the 1st stage are calculated by Transmission Disequilibrium Test (TDT). P values of the 2nd stage are calculated by Fisher's exact test. HWE: Hardy Weinberg Equilibrium. Departures from the assumption of HWE are evaluated based on the data from the 2nd stage case-control samples.

Stage III: Replication in Chinese family samples collected by NIMH

Japanese and Chinese are genetically close, but apparently different populations. In addition, the gene-based approach provides more information than single-SNP analysis, because a high-density mapping could capture the potential risk-conferring variations, which is difficult by examining sparse-density SNPs on the GeneChip. Accordingly, to confirm association signals in a gene-based manner, we performed a follow-up study of the ELAVL2 gene whose SNP showed the most compelling association in the case-control study using Japanese population, by densely genotyping 293 pedigree samples (284 quad and 9 trio samples, consisting of 1,163 family members) from Chinese population. We analyzed 56 tagSNPs located in and around the ELAVL2 gene. This gene has not been reported to be genetically associated with schizophrenia to date. As shown in Figure 3, single marker analysis in the third set showed a nominally significant association with four SNPs on the gene (lowest p = 0.026). Three SNPs are clustered in the intron 1 of the gene. They lose significance when conservative Bonferroni's correction was applied. The transmitted/non-transmitted and overrepresentation/underrepresentation relationship of the allele revealed consistent risk of the minor C allele of the initial marker SNP (rs10491817) in each stage sample. The significant SNPs on the ELAVL2 gene showed no deviation from Hardy-Weinberg disequilibrium (based on the data from independent parents in the Chinese sample set).
Figure 3

Genomic structure of ELAVL2 and gene-centric association analysis.

Genomic structure and locations of genetic markers in and around ELAVL2 are shown, with chromosomal positions according to the human genome database (http://genome.ucsc.edu/) on the top. Exons of the gene are denoted by boxes. The negative logarithm of p value for association is plotted as a function of chromosomal positions of SNP markers. Bold line indicates p value of <0.05.

Genomic structure of ELAVL2 and gene-centric association analysis.

Genomic structure and locations of genetic markers in and around ELAVL2 are shown, with chromosomal positions according to the human genome database (http://genome.ucsc.edu/) on the top. Exons of the gene are denoted by boxes. The negative logarithm of p value for association is plotted as a function of chromosomal positions of SNP markers. Bold line indicates p value of <0.05.

Quantitative RT-PCR in postmortem brains from schizophrenia

The identification of ELAVL2 as a susceptibility gene for schizophrenia in both Japanese and Chinese cohorts led us to examine whether the expression levels of the gene are altered in the postmortem brains of patients with schizophrenia. In addition, the accumulating lines of evidence show that schizophrenia and bipolar disorder partly share common susceptibility genes or genetic pathways. We performed real-time quantitative RT-PCR assays for mRNA levels of the gene in the dorsolateral prefrontal cortex (DLPFC: Brodmann's area 46) of schizophrenia, bipolar disorder and control brains. However, the experiments showed that the expression levels of ELAVL2 were not different among brains from schizophrenics, bipolar disorder patients and control subjects (Figure 4). We did not examine the allele-specific expression levels of the transcript because the minor allele (C) frequency is very low (0.056) in Caucasian (from which the postmortem brains are derived) according to the HapMap database (http://hapmap.ncbi.nlm.nih.gov/).
Figure 4

Quantitative RT-PCR in postmortem brains.

Rectangles and triangles represent individuals. The horizontal bars delineate the mean of each group. The expression levels of ELAVL2 were not significantly different among postmortem brains from schizophrenics, bipolar disorder patients and controls in the dorsolateral prefrontal cortex.

Quantitative RT-PCR in postmortem brains.

Rectangles and triangles represent individuals. The horizontal bars delineate the mean of each group. The expression levels of ELAVL2 were not significantly different among postmortem brains from schizophrenics, bipolar disorder patients and controls in the dorsolateral prefrontal cortex.

Discussion

We performed a GWAS, a follow-up replication study and a gene-centric dense mapping to identify susceptibility genes and risk variants for schizophrenia in Japanese and Chinese populations. A novel candidate gene has emerged from our staged association analyses. ELAVL2 [(embryonic lethal, abnormal vision, Drosophila)-like 2], also known as Hu antigen B (HuB) or Hel-N1, belongs to the RNA-binding Hu (Elavl) protein family. In mammals, the family consists of four highly conserved members that include the ubiquitously expressed ELAVL1 (HuA, HuR) and the neuronal-specific ELAVL2 (HuB, Hel- N1), ELAVL3 (HuC, ple21) and ELAVL4 (HuD) [10], [11], [12], [13], [14]. Neuronal Elavl proteins (nELAVL; ELAVL2, ELAVL3 and ELAVL4) have been identified as splicing regulators in neuron-like cells, and are likely to exert critical posttranscriptional control as key inducers of programmed neuronal differentiation and function in the mammalian nervous system [15], [16]. Given their role in neuronal differentiation and plasticity, nELAVL proteins including ELAVL2 could be potential candidates for neurodegenerative and psychiatric diseases. Indeed, recent studies implicate ELAVL4 as a Parkinson's disease susceptibility gene [17], [18]. Noteworthy, the altered expression of GAP43, one of known targets of ELAVL4, is reported in the frontal cortices and the hippocampus of patients with schizophrenia [19], [20], [21], [22], [23]. Although their relevance to schizophrenia pathogenesis is still awaiting clarification, they are worthy of further investigation. In this work, we have attempted to minimize several limitations often plaguing association studies in psychiatry. Firstly, to minimize population stratification and genetic heterogeneity, we have focused on trio samples of Japanese descent at the first stage. Secondly, we conducted a replication study for significant SNPs using case-control samples from the same Japanese population but an independent sample set at the second stage. Finally, to confirm the association in an ethnically close but different population, we analyzed patient-parents trios/quads of Chinese descent at the third stage. In this stage, to achieve greater coverage of genetic variations for the survived gene, we performed gene-centric analysis by selecting 56 tag SNPs throughout the entire region of the gene (150 kb). However, several limitations must be considered. We have not achieved sufficient SNP coverage in the first stage of this study, and the number of samples is modest to detect small to medium effect of a disease-associated gene at genome-wide significance level. When Bonferroni's correction was applied, the significant p value was 5.10×10−7 for multiple tests of 97,963 SNPs ( = 0.05/97,963). The most significant p value in the first stage analysis (p = 6.11×10−6) loses significance after conservative correction. In addition, a small number of genuine causal variants will be buried within a larger number of SNPs with nominal associations. Therefore, the current study will require a follow-up analysis to distinguish the small number of genuine causal variants from the high proportion of SNPs with false-positive associations. The ELAVL2 gene showed a nominal significance at each stage. However, the initial marker SNP in Japanese population (rs10491817) was not significant in Chinese population (p = 0.082). This may reflect the allelic heterogeneity of the gene, because the significant markers in both populations were not in tight linkage disequilibrium (Figures S1, S2). In this context, the gene warrants further investigation. Recently, Ikeda and his colleagues reported the first GWAS for schizophrenia in Japanese population [1]. In the study, the strongest associations were observed at rs12218361 mapped near the 3′ end of the OAT (a gene for ornithine aminotransferase) on 10q26.13 and rs11895771 mapped within the SULT6B1 (a gene for sulfotransferase family, cytosolic, 6B, member 1) on 2p22.2 (p = 7.2×10−8 and p = 6.2×10−6, respectively). No significant associations for those genes were observed in this study. However, it is noteworthy that the two Japanese studies gave the same gene of nominal significance, C6orf105 (Table 1). This putative gene is reported as a candidate for non-syndromic oral clefts [24], but its exact function is unknown. Recent studies show suggestive evidence of association of multiple GABA-related genes with schizophrenia [25], [26]. One of the benefits obtained from GWAS is that we can examine whether a subset of genes categorized into some signaling pathway are involved in the pathogeneses of disease, beyond single genes [27]. We pursued this issue using the first-stage GWAS dataset and unveiled the accumulation of association signals from genes of GABAergic pathways in schizophrenia. Association signature on GABA-related loci was identified across several human chromosomes, which is particularly highlighted on chromosome 5q34 (Figure S3). However, most of the SNPs in and around GABA-related genes associated with schizophrenia in our first-stage dataset were not confirmed in the second-stage samples. Only rs10515831, which lies 90 kb downstream of GABRB2, 47 kb upstream of GABRA6 and 209 kb upstream of GABRA1 on 5q34, showed a nominal significant association with the disease in the second-stage analysis (p = 0.033). This may be due to weak genetic contributions of these genes in Japanese, suggesting the necessity of a much larger number of second-stage samples. In summary, we provided a suggestive evidence for the contribution of ELAVL2 to the pathogenesis of schizophrenia, in both Japanese and Chinese populations. This prioritized gene deserves further evaluation to improve the understanding of schizophrenia genetics.

Materials and Methods

Samples

A three-stage analysis was performed by using two independent Japanese cohorts and an ethnically close Chinese population. In the first stage, 120 patient-parents trio samples from Japanese schizophrenia pedigrees (360 members) were analyzed. In the second stage, case–control samples consisted of 1,012 unrelated individuals (506 schizophrenia patients, mean age 49.2±13.0 years; 506 age- and sex-matched controls, mean age 49.2±13.0 years). In the third stage, Chinese sample consisted of 293 pedigrees (1,163 subjects: nine trios and 284 quads) collected by the NIMH initiative (http://nimhgenetics.org/). For the Japanese samples, all the subjects resided in central Japan. Consensual diagnoses were made by at least two experienced psychiatrists according to DSM-IV criteria. Written informed consent was obtained from all the participants, after the provision and an explanation of study protocols and purposes. Our case samples in the current study consist of all such patients with schizophrenia who are in a remission/stable chronic state and possess the ability to agree to join the research. This study was approved by the Ethics Committee of RIKEN, and conducted according to the principles expressed in the Declaration of Helsinki.

First-stage analysis

The first-stage GWAS was performed using Affymetrix GeneChip Mapping 100 K microarrays (Affymetrix, Santa Clara, CA) following the manufacturer's protocol. Genotype data were analyzed with the GeneSpring GT (Varia) 2.0 software package developed by Agilent Technologies (Santa Clara, CA). Transmission disequilibrium test was performed using the R program (http://www.r-project.org). We set a liberal first-stage significance level to increase the potential to detect associated genes with small effects in the subsequent stage analyses: (i) p value<0.01, and (ii) p value<0.05 when SNPs are located in candidate chromosomal regions detected in the meta-analysis of schizophrenia linkage studies [9] or in the reported linkage regions of Japanese population [8]. We used the Haploview 4.2 to create a Manhattan plot of p values from GWAS study (http://www.broadinstitute.org/haploview). A QQ plot of p values from GWAS was created using R scripts provided by Diabetes Genetics Initiative (http://www.broadinstitute.org/science/projects/diabetes-genetics-initiative/plotting-genome-wide-association-results). The data obtained in this study have been deposited into the NCBI's Gene Expression Omnibus [28] and are accessible through GEO Series accession number GSE27923 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27923).

Second-stage analysis

In the second stage, genotyping was performed using Illumina (San Diego, CA), through the use of their Integrated BeadArray System. We supplied Illumina with 96-well barcoded DNA microtiter plates containing 1,012 samples of DNA (4 mg each) quantified with Pico Green to be 100 ng/ml. Assay quality was as follows: sample success rate of 100%, locus success rate of 97.40%, genotype call rate of 99.98%, reproducibility of 99.997% and genotyping concordance of 99.93%. These results indicate that genotyping was highly accurate and reproducible in this study. Statistical analysis of allelic association was performed using the R program.

Gene-centric association study

In a gene-centric association study, SNP genotyping was performed using the TaqMan system (Applied Biosystems, Foster City, CA) following the manufacturer's recommendation. PCR was performed using an ABI 9700 thermocycler, and fluorescent signals were analyzed on an ABI 7900HT Fast real-time PCR System using Sequence Detection Software (SDS) v2.3 (Applied Biosystems). TagSNPs were selected using the ldSelect software (http://droog.gs.washington.edu/ldSelect.html) based on their r values of 0.8 as a cut-off point to capture genotype information. We genotyped 56 tagSNPs located in and around the ELAVL2 gene in the stage III. The genetic association was evaluated using the Family-Based Association Test (FBAT) program (v2.0.3, http://www.biostat.harvard.edu/~fbat/).

Brain tissues and quantitative RT-PCR

RNA from the dorsolateral prefrontal cortex (Brodmann's area 46) was obtained from the Stanley Medical Research Institute (http://sncid.stanleyresearch.org/) [29], [30]. Brain samples were taken from 35 schizophrenics [26 males, 9 females; mean ± SD age, 42.6±8.5 years; postmortem interval (PMI), 31.4±15.5 h; brain pH, 6.5±0.2], 35 bipolar disorder patients (17 males, 18 females; mean ± SD age, 45.3±10.5 years; PMI, 37.9±18.3 h; brain pH, 6.4±0.3), and 35 controls (26 males, 9 females; mean ± SD age, 44.2±7.6 years; PMI, 29.4±12.9 h; brain pH, 6.6±0.3). Diagnoses were made in accordance with DSM-IV criteria. There were no significant demographic differences between the schizophrenia, bipolar and control brains, in terms of age, postmortem interval and sample pH. All the patients with schizophrenia were administered with anti-psychotics. Quantitative RT-PCR analysis was conducted using an ABI7900HT Fast Real-Time PCR System (Applied Biosystems). TaqMan probes and primers for ELAVL2 and GAPDH (an internal control) were Assay-on-Demand™ or Assay-by-Design™ gene expression products (Applied Biosystems). All the quantitative RT-PCR reactions were performed in triplicate, based on a standard curve method. The Mann-Whitney U test (two–tailed) was used to evaluate significant changes in target gene expression levels. Replication in Japanese case-control samples (autosomes). SNP information is based on the UCSC database (http://genome.ucsc.edu/). P values of the 1st stage analysis are calculated by Transmission Disequilibrium Test (TDT). P values of the 2nd stage analysis are calculated by Fisher's exact test. HWE: Hardy Weinberg Equilibrium. Departures from the assumption of HWE are evaluated based on the data from the 2nd stage case-control samples. (XLS) Click here for additional data file. Replication in Japanese case-control samples (chromosome X). SNP information is based on the UCSC database (http://genome.ucsc.edu/). P values of the 1st stage analysis are calculated by Transmission Disequilibrium Test (TDT). P values of the 2nd stage analysis are calculated by Fisher's exact test. (XLS) Click here for additional data file. Linkage disequilibrium between markers in Chinese population. Linkage disequilibrium (LD) between markers constructed by the Haploview program is shown (based on the data from independent parents in the Chinese sample set). The number in each cell represents the LD parameter r (×100). Each cell is painted with graduated color relative to the strength of linkage disequilibrium between markers. The rs numbers are SNP I.D. in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/snp). The significant SNPs and the genomic region surrounding these SNPs were shown in red and a red pentagon, respectively. (TIF) Click here for additional data file. Linkage disequilibrium between markers in Japanese population. Linkage disequilibrium (LD) between markers constructed by the Haploview program using the data from HapMap database is shown (http://hapmap.ncbi.nlm.nih.gov/). The number in each cell represents the LD parameter r (×100). Each cell is painted with graduated color relative to the strength of linkage disequilibrium between markers. The rs numbers are SNP I.D. in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/snp). The significant SNPs and the genomic region surrounding these SNPs were shown in red and a red pentagon, respectively. (TIF) Click here for additional data file. Association signals on chromosome 5q GABA The chromosome 5q risk locus contains a cluster of GABAA receptor subunit genes, GABRB2, GABRA6, GABRA1, GABRG2 and GABRP. Significant SNPs (p<0.05) and the corresponding genes are shown in red. (TIF) Click here for additional data file.
  30 in total

1.  A nuclear function of Hu proteins as neuron-specific alternative RNA processing regulators.

Authors:  Hui Zhu; Robert A Hasman; Victoria A Barron; Guangbin Luo; Hua Lou
Journal:  Mol Biol Cell       Date:  2006-10-11       Impact factor: 4.138

2.  Identification of loci associated with schizophrenia by genome-wide association and follow-up.

Authors:  Michael C O'Donovan; Nicholas Craddock; Nadine Norton; Hywel Williams; Timothy Peirce; Valentina Moskvina; Ivan Nikolov; Marian Hamshere; Liam Carroll; Lyudmila Georgieva; Sarah Dwyer; Peter Holmans; Jonathan L Marchini; Chris C A Spencer; Bryan Howie; Hin-Tak Leung; Annette M Hartmann; Hans-Jürgen Möller; Derek W Morris; Yongyong Shi; GuoYin Feng; Per Hoffmann; Peter Propping; Catalina Vasilescu; Wolfgang Maier; Marcella Rietschel; Stanley Zammit; Johannes Schumacher; Emma M Quinn; Thomas G Schulze; Nigel M Williams; Ina Giegling; Nakao Iwata; Masashi Ikeda; Ariel Darvasi; Sagiv Shifman; Lin He; Jubao Duan; Alan R Sanders; Douglas F Levinson; Pablo V Gejman; Sven Cichon; Markus M Nöthen; Michael Gill; Aiden Corvin; Dan Rujescu; George Kirov; Michael J Owen; Nancy G Buccola; Bryan J Mowry; Robert Freedman; Farooq Amin; Donald W Black; Jeremy M Silverman; William F Byerley; C Robert Cloninger
Journal:  Nat Genet       Date:  2008-09       Impact factor: 38.330

Review 3.  Defining a neuron: neuronal ELAV proteins.

Authors:  A Pascale; M Amadio; A Quattrone
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

4.  Immunoreactivity of 43 kDa growth-associated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia.

Authors:  Simon Y Tian; Jun-Feng Wang; Yarema B Bezchlibnyk; L Trevor Young
Journal:  Neurosci Lett       Date:  2006-11-13       Impact factor: 3.046

5.  Common variants on chromosome 6p22.1 are associated with schizophrenia.

Authors:  Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

6.  Replication of association between ELAVL4 and Parkinson disease: the GenePD study.

Authors:  Anita L DeStefano; Jeanne Latourelle; Mark F Lew; Oksana Suchowersky; Christine Klein; Lawrence I Golbe; Margery H Mark; John H Growdon; G Fredrick Wooten; Ray Watts; Mark Guttman; Brad A Racette; Joel S Perlmutter; Lynn Marlor; Holly A Shill; Carlos Singer; Stefano Goldwurm; Gianni Pezzoli; Marie H Saint-Hilaire; Audrey E Hendricks; Adam Gower; Sally Williamson; Michael W Nagle; Jemma B Wilk; Tiffany Massood; Karen W Huskey; Kenneth B Baker; Ilia Itin; Irene Litvan; Garth Nicholson; Alastair Corbett; Martha Nance; Edward Drasby; Stuart Isaacson; David J Burn; Patrick F Chinnery; Peter P Pramstaller; Jomana Al-Hinti; Anette T Moller; Karen Ostergaard; Scott J Sherman; Richard Roxburgh; Barry Snow; John T Slevin; Franca Cambi; James F Gusella; Richard H Myers
Journal:  Hum Genet       Date:  2008-06-29       Impact factor: 4.132

7.  Strong association of de novo copy number mutations with sporadic schizophrenia.

Authors:  Bin Xu; J Louw Roos; Shawn Levy; E J van Rensburg; Joseph A Gogos; Maria Karayiorgou
Journal:  Nat Genet       Date:  2008-05-30       Impact factor: 38.330

8.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder.

Authors:  Shaun M Purcell; Naomi R Wray; Jennifer L Stone; Peter M Visscher; Michael C O'Donovan; Patrick F Sullivan; Pamela Sklar
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

9.  Common variants conferring risk of schizophrenia.

Authors:  Hreinn Stefansson; Roel A Ophoff; Stacy Steinberg; Ole A Andreassen; Sven Cichon; Dan Rujescu; Thomas Werge; Olli P H Pietiläinen; Ole Mors; Preben B Mortensen; Engilbert Sigurdsson; Omar Gustafsson; Mette Nyegaard; Annamari Tuulio-Henriksson; Andres Ingason; Thomas Hansen; Jaana Suvisaari; Jouko Lonnqvist; Tiina Paunio; Anders D Børglum; Annette Hartmann; Anders Fink-Jensen; Merete Nordentoft; David Hougaard; Bent Norgaard-Pedersen; Yvonne Böttcher; Jes Olesen; René Breuer; Hans-Jürgen Möller; Ina Giegling; Henrik B Rasmussen; Sally Timm; Manuel Mattheisen; István Bitter; János M Réthelyi; Brynja B Magnusdottir; Thordur Sigmundsson; Pall Olason; Gisli Masson; Jeffrey R Gulcher; Magnus Haraldsson; Ragnheidur Fossdal; Thorgeir E Thorgeirsson; Unnur Thorsteinsdottir; Mirella Ruggeri; Sarah Tosato; Barbara Franke; Eric Strengman; Lambertus A Kiemeney; Ingrid Melle; Srdjan Djurovic; Lilia Abramova; Vasily Kaleda; Julio Sanjuan; Rosa de Frutos; Elvira Bramon; Evangelos Vassos; Gillian Fraser; Ulrich Ettinger; Marco Picchioni; Nicholas Walker; Timi Toulopoulou; Anna C Need; Dongliang Ge; Joeng Lim Yoon; Kevin V Shianna; Nelson B Freimer; Rita M Cantor; Robin Murray; Augustine Kong; Vera Golimbet; Angel Carracedo; Celso Arango; Javier Costas; Erik G Jönsson; Lars Terenius; Ingrid Agartz; Hannes Petursson; Markus M Nöthen; Marcella Rietschel; Paul M Matthews; Pierandrea Muglia; Leena Peltonen; David St Clair; David B Goldstein; Kari Stefansson; David A Collier
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

10.  Large recurrent microdeletions associated with schizophrenia.

Authors:  Hreinn Stefansson; Dan Rujescu; Sven Cichon; Olli P H Pietiläinen; Andres Ingason; Stacy Steinberg; Ragnheidur Fossdal; Engilbert Sigurdsson; Thordur Sigmundsson; Jacobine E Buizer-Voskamp; Thomas Hansen; Klaus D Jakobsen; Pierandrea Muglia; Clyde Francks; Paul M Matthews; Arnaldur Gylfason; Bjarni V Halldorsson; Daniel Gudbjartsson; Thorgeir E Thorgeirsson; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Aslaug Jonasdottir; Asgeir Bjornsson; Sigurborg Mattiasdottir; Thorarinn Blondal; Magnus Haraldsson; Brynja B Magnusdottir; Ina Giegling; Hans-Jürgen Möller; Annette Hartmann; Kevin V Shianna; Dongliang Ge; Anna C Need; Caroline Crombie; Gillian Fraser; Nicholas Walker; Jouko Lonnqvist; Jaana Suvisaari; Annamarie Tuulio-Henriksson; Tiina Paunio; Timi Toulopoulou; Elvira Bramon; Marta Di Forti; Robin Murray; Mirella Ruggeri; Evangelos Vassos; Sarah Tosato; Muriel Walshe; Tao Li; Catalina Vasilescu; Thomas W Mühleisen; August G Wang; Henrik Ullum; Srdjan Djurovic; Ingrid Melle; Jes Olesen; Lambertus A Kiemeney; Barbara Franke; Chiara Sabatti; Nelson B Freimer; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Ole A Andreassen; Roel A Ophoff; Alexander Georgi; Marcella Rietschel; Thomas Werge; Hannes Petursson; David B Goldstein; Markus M Nöthen; Leena Peltonen; David A Collier; David St Clair; Kari Stefansson
Journal:  Nature       Date:  2008-09-11       Impact factor: 49.962

View more
  35 in total

Review 1.  Behavioral and Genetic Evidence for GIRK Channels in the CNS: Role in Physiology, Pathophysiology, and Drug Addiction.

Authors:  Jody Mayfield; Yuri A Blednov; R Adron Harris
Journal:  Int Rev Neurobiol       Date:  2015-06-22       Impact factor: 3.230

Review 2.  The complex world of post-transcriptional mechanisms: is their deregulation a common link for diseases? Focus on ELAV-like RNA-binding proteins.

Authors:  Alessia Pascale; Stefano Govoni
Journal:  Cell Mol Life Sci       Date:  2011-09-10       Impact factor: 9.261

3.  Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder.

Authors:  Liping Hou; Sarah E Bergen; Nirmala Akula; Jie Song; Christina M Hultman; Mikael Landén; Mazda Adli; Martin Alda; Raffaella Ardau; Bárbara Arias; Jean-Michel Aubry; Lena Backlund; Judith A Badner; Thomas B Barrett; Michael Bauer; Bernhard T Baune; Frank Bellivier; Antonio Benabarre; Susanne Bengesser; Wade H Berrettini; Abesh Kumar Bhattacharjee; Joanna M Biernacka; Armin Birner; Cinnamon S Bloss; Clara Brichant-Petitjean; Elise T Bui; William Byerley; Pablo Cervantes; Caterina Chillotti; Sven Cichon; Francesc Colom; William Coryell; David W Craig; Cristiana Cruceanu; Piotr M Czerski; Tony Davis; Alexandre Dayer; Franziska Degenhardt; Maria Del Zompo; J Raymond DePaulo; Howard J Edenberg; Bruno Étain; Peter Falkai; Tatiana Foroud; Andreas J Forstner; Louise Frisén; Mark A Frye; Janice M Fullerton; Sébastien Gard; Julie S Garnham; Elliot S Gershon; Fernando S Goes; Tiffany A Greenwood; Maria Grigoroiu-Serbanescu; Joanna Hauser; Urs Heilbronner; Stefanie Heilmann-Heimbach; Stefan Herms; Maria Hipolito; Shashi Hitturlingappa; Per Hoffmann; Andrea Hofmann; Stephane Jamain; Esther Jiménez; Jean-Pierre Kahn; Layla Kassem; John R Kelsoe; Sarah Kittel-Schneider; Sebastian Kliwicki; Daniel L Koller; Barbara König; Nina Lackner; Gonzalo Laje; Maren Lang; Catharina Lavebratt; William B Lawson; Marion Leboyer; Susan G Leckband; Chunyu Liu; Anna Maaser; Pamela B Mahon; Wolfgang Maier; Mario Maj; Mirko Manchia; Lina Martinsson; Michael J McCarthy; Susan L McElroy; Melvin G McInnis; Rebecca McKinney; Philip B Mitchell; Marina Mitjans; Francis M Mondimore; Palmiero Monteleone; Thomas W Mühleisen; Caroline M Nievergelt; Markus M Nöthen; Tomas Novák; John I Nurnberger; Evaristus A Nwulia; Urban Ösby; Andrea Pfennig; James B Potash; Peter Propping; Andreas Reif; Eva Reininghaus; John Rice; Marcella Rietschel; Guy A Rouleau; Janusz K Rybakowski; Martin Schalling; William A Scheftner; Peter R Schofield; Nicholas J Schork; Thomas G Schulze; Johannes Schumacher; Barbara W Schweizer; Giovanni Severino; Tatyana Shekhtman; Paul D Shilling; Christian Simhandl; Claire M Slaney; Erin N Smith; Alessio Squassina; Thomas Stamm; Pavla Stopkova; Fabian Streit; Jana Strohmaier; Szabolcs Szelinger; Sarah K Tighe; Alfonso Tortorella; Gustavo Turecki; Eduard Vieta; Julia Volkert; Stephanie H Witt; Adam Wright; Peter P Zandi; Peng Zhang; Sebastian Zollner; Francis J McMahon
Journal:  Hum Mol Genet       Date:  2016-06-21       Impact factor: 6.150

Review 4.  Genetics of schizophrenia from a clinicial perspective.

Authors:  Prachi Kukshal; B K Thelma; Vishwajit L Nimgaonkar; Smita N Deshpande
Journal:  Int Rev Psychiatry       Date:  2012-10

5.  Involvement of PTPN5, the gene encoding the striatal-enriched protein tyrosine phosphatase, in schizophrenia and cognition.

Authors:  Ilana Pelov; Omri Teltsh; Lior Greenbaum; Amihai Rigbi; Kyra Kanyas-Sarner; Bernard Lerer; Paul Lombroso; Yoav Kohn
Journal:  Psychiatr Genet       Date:  2012-08       Impact factor: 2.458

6.  Prenatal protein malnutrition decreases KCNJ3 and 2DG activity in rat prefrontal cortex.

Authors:  A C Amaral; M Jakovcevski; J A McGaughy; S K Calderwood; D J Mokler; R J Rushmore; J R Galler; S A Akbarian; D L Rosene
Journal:  Neuroscience       Date:  2014-11-18       Impact factor: 3.590

7.  G Protein-Gated K+ Channel Ablation in Forebrain Pyramidal Neurons Selectively Impairs Fear Learning.

Authors:  Nicole C Victoria; Ezequiel Marron Fernandez de Velasco; Olga Ostrovskaya; Stefania Metzger; Zhilian Xia; Lydia Kotecki; Michael A Benneyworth; Anastasia N Zink; Kirill A Martemyanov; Kevin Wickman
Journal:  Biol Psychiatry       Date:  2015-11-10       Impact factor: 13.382

8.  Human-specific transcriptional networks in the brain.

Authors:  Genevieve Konopka; Tara Friedrich; Jeremy Davis-Turak; Kellen Winden; Michael C Oldham; Fuying Gao; Leslie Chen; Guang-Zhong Wang; Rui Luo; Todd M Preuss; Daniel H Geschwind
Journal:  Neuron       Date:  2012-08-23       Impact factor: 17.173

9.  ELAVL2-regulated transcriptional and splicing networks in human neurons link neurodevelopment and autism.

Authors:  Stefano Berto; Noriyoshi Usui; Genevieve Konopka; Brent L Fogel
Journal:  Hum Mol Genet       Date:  2016-06-03       Impact factor: 6.150

10.  Individual risk alleles of susceptibility to schizophrenia are associated with poor clinical and social outcomes.

Authors:  Shinji Sakamoto; Manabu Takaki; Yuko Okahisa; Yutaka Mizuki; Masatoshi Inagaki; Hiroshi Ujike; Toshiharu Mitsuhashi; Soshi Takao; Masashi Ikeda; Yosuke Uchitomi; Nakao Iwata; Norihito Yamada
Journal:  J Hum Genet       Date:  2015-12-17       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.